Skip to main content

Advertisement

SpringerLink
Log in

Nuclear medicine in the treatment of neuroendocrine tumours—problems and perspectives

  • Editorial
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rindi G, Villanacci V, Ubiali A, Scarpa A. Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 2001;1:323–33.

    Article  PubMed  CAS  Google Scholar 

  2. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458–511.

    Article  PubMed  CAS  Google Scholar 

  3. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med 2004;48:150–63.

    CAS  Google Scholar 

  4. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704–13.

    PubMed  CAS  Google Scholar 

  5. Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann NY Acad Sci 1994;733:122–37.

    Article  PubMed  CAS  Google Scholar 

  6. Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cycle arrest. Mol Endocrinol 1999;13:82–90.

    Article  PubMed  CAS  Google Scholar 

  7. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000;62:33–8.

    Article  PubMed  CAS  Google Scholar 

  8. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002;8:1781–807.

    Article  PubMed  CAS  Google Scholar 

  9. de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133–40.

    Article  PubMed  Google Scholar 

  10. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28–47.

    Article  PubMed  CAS  Google Scholar 

  11. Jenkins SA, Kynaston HG, Davies ND, Baxter JN, Nott DM. Somatostatin analogs in oncology: a look. Chemotherapy 2001;47(Suppl 2):162–96.

    Article  PubMed  CAS  Google Scholar 

  12. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995;36:1825–35.

    PubMed  CAS  Google Scholar 

  13. Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S. The current status of radioiodinated metaiodobenzylguanidine therapy of neuro-endocrine tumors. Q J Nucl Med 1995;34:55–7.

    Google Scholar 

  14. Troncone L, Ruffini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 1999;43:344–55.

    PubMed  CAS  Google Scholar 

  15. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24:1546–53.

    Article  PubMed  CAS  Google Scholar 

  16. Wang C, Mirkin BL, Dwivedi RS. DNA (cytosine) methyltransferase overexpression is associated with acquired drug resistance of murine neuroblastoma cells. Int J Oncol 2001;18:323–9.

    PubMed  CAS  Google Scholar 

  17. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66:8847–57.

    Article  PubMed  CAS  Google Scholar 

  18. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697–704.

    Article  PubMed  CAS  Google Scholar 

  19. Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2, and hOCT3. Br J Pharmacol 2002;136:829–36.

    Article  PubMed  CAS  Google Scholar 

  20. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–45.

    Article  PubMed  CAS  Google Scholar 

  21. Perez-Tomas R. Multidrug resistance: retrospects and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13:1859–76.

    Article  PubMed  CAS  Google Scholar 

  22. Chudzinski W, Niderla J, Lasiecka Z, Wilczynski G, Gornicka B, Wasiutynski A, et al. P-glycoprotein expression influences the result of 99mTc-MIBI scintigraphy in tertiary hyperparathyroidism. Int J Mol Med 2005;16:215–20.

    PubMed  CAS  Google Scholar 

  23. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001;132:1183–92.

    Article  PubMed  CAS  Google Scholar 

  24. Pallis M, Turzanski J, Higashi Y, Russel N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis resistant phenotype. Leuk Lymphoma 2002;43:1221–8.

    Article  PubMed  CAS  Google Scholar 

  25. Hendrikse NH, Franssren EJF, van der Graaf WTA, Meijer C, Piers DA, Vaalburg W, et al. 99mTc-MIBI is a substrate for P-glycoprotein and the multidrug associated protein. Br J Cancer 1998;77:9675–82.

    Google Scholar 

  26. Grzela T, Chudzinski W, Lazarczyk M, Niderla J, Dziunycz P, Milewski L, et al. Persisted/recurrent hyperparathyroidism associated with development of multi-drug resistance phenotype and proliferation of parathyroid transplants. Int J Mol Med 2004;14:595–600.

    PubMed  CAS  Google Scholar 

  27. Bader P, Schilling F, Schlaud M, Girgert R, Handgretinger R, Klingebiel T, et al. Expression analysis of multidrug resistance associated genes in neuroblastomas. Oncol Rep 1999;6:1143–6.

    PubMed  CAS  Google Scholar 

  28. Albolhoda A, Wilson AE, Ross H, Dannenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999;5:3352–6.

    Google Scholar 

  29. Lu QJ, Dong F, Zhang JH, Li XH, Ma Y, Jiang WG. Expression of multidrug resistance-related markers in primary neuroblastoma. Chin Med J 2004;117:1358–63.

    PubMed  Google Scholar 

  30. Singhal SS, Yadav S, Singhal J, Zajac E, Awasthi Y, Awasthi S. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Bioch Pharm 2005;70:481–8.

    Article  CAS  Google Scholar 

  31. Singhal SS, Awasthi YC, Awasthi S. Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res 2006;66:2354–60.

    Article  PubMed  CAS  Google Scholar 

  32. Awasthi S, Singhal SS, Yadav S, Singhal J, Drake K, Nadkar A, et al. RLIP76 is a major determinant of radiation sensitivity. Cancer Res 2005;65:6022–8.

    Article  PubMed  CAS  Google Scholar 

  33. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22:7414–30.

    Article  PubMed  CAS  Google Scholar 

  34. Del Vecchio S, Zannetti A, Aloj L, Caraco C, Ciarmiello A, Salvatore M. Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. Eur J Med Mol Imaging 2003;30:879–87.

    Article  CAS  Google Scholar 

  35. Schipper ML, Weber A, Behe M, Goke R, Joba W, Schmidt H, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res 2003;63:1333–8.

    PubMed  CAS  Google Scholar 

  36. Strauss HW. Nuclear medicine 2020. Q J Nucl Med 2006;50:1–3.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Cell Biology Laboratory, Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland

    Tomasz Grzela, Agata Bialoszewska & Robert Brawura-Biskupski-Samaha

Authors
  1. Tomasz Grzela
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Agata Bialoszewska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Brawura-Biskupski-Samaha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomasz Grzela.

Additional information

This editorial commentary refers to the article http://dx.doi.org/10.1007/s00259-006-0256-6.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grzela, T., Bialoszewska, A. & Brawura-Biskupski-Samaha, R. Nuclear medicine in the treatment of neuroendocrine tumours—problems and perspectives. Eur J Nucl Med Mol Imaging 34, 444–447 (2007). https://doi.org/10.1007/s00259-006-0300-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-006-0300-6

Search

Navigation